

In the Claims:


In accordance with 37 CFR § 1.121, please substitute for original claim 1, the following rewritten version of the same claim, as amended. The changes are shown explicitly in the attached "Marked Up Version Showing Changes Made."

Please cancel claims ~~4, 5 and 7~~ without prejudice or disclaimer.

Please amend the following claim.

1. (Twice Amended) A method of determining an efficacious dose of a compound administered to a subject for the purpose of modulating angiogenesis, comprising the steps of:

(a) administering the compound to a patient, wherein the compound is a receptor antagonist that inhibits a receptor involved in angiogenesis and wherein the compound is an indolinone compound, having the structure set forth in formula I:



wherein

(i) R1, R2, R3, and R4 are selected from the group consisting of hydrogen, trihalomethyl, hydroxyl, amine, thioether, cyano, alkoxy, alkyl, amino, bromo, fluoro, chloro, iodo, mercapto, thio, cyanoamido, alkylthio,

aryl, heteroaryl, carboxyl, ester, oxo, alkoxy carbonyl, alkenyl, alkoxy, nitro, alkoxy, and amido moieties; and

(ii) R5, is an optionally substituted aryl or heteroaryl cyclic moiety;

or a pharmaceutically acceptable salt, ester, amide, prodrug, isomer, or metabolite thereof;

(b) monitoring a marker selected from the group consisting of tissue factor, CD40, u-PA, ETS-1, IL8, and t-PA;

(c) constructing a standard curve; and

(d) determining the efficacious dose based on the standard curve.